SUBLINGUAL APOMORPHINE IN PARKINSON'S DISEASE--TOLERABILITY AND EFFICACY

舌下含服阿扑吗啡治疗帕金森病——耐受性和疗效

• 批准号: 6278162
• 负责人: STEPHEN T GANCHER
• 金额: $ 2.86万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6278162
• 关键词: Parkinson's disease; antiparkinson drugs; apomorphine; clinical research; clinical trials; drug administration rate /duration; drug administration routes; drug adverse effect; drug screening /evaluation; drug tolerance; human subject; human therapy evaluation; mental disorder chemotherapy; psychomotor function

This is a trial of sublingual apomorphine for the treatment of motor fluctuations in patients with Parkinson's disease. Following an inpatient dose titration and a single-dose, double-blind treatment to evaluate initial side effects and efficacy, apomorphine will be used as adjunctive treatment for eight weeks.

这是一个试验舌下阿扑吗啡治疗运动 帕金森病患者的情绪波动。 一个住院病人 剂量滴定和单次给药、双盲治疗，以评估 阿扑吗啡将被用作预防药物， 治疗8周。